Back to
Updated on June 23, 2025
In biology, a pathway is a sequence of events that occur at the molecular level. For a simple illustration, think of a pathway as a line of dominoes, where tipping over the first domino triggers the second domino to fall, which triggers the third, and so on. The tipping of the first domino could be the arrival of a hormone, enzyme, or some other chemical change that causes a reaction.
Pathways are constantly at work, controlling things like temperature, metabolism, immune responses, movement, reproductive function, and many other processes throughout the body.
Here, we will focus on a specific example, the melanocortin-4 receptor (MC4R) pathway. This pathway plays a vital role in regulating appetite, hunger, satiety, and eating behavior. It occurs in the hypothalamus, an almond-sized structure located at the base of the brain, just above the brain stem (the part of the brain that connects to the spinal cord).
Damage to the hypothalamus can disrupt how the MC4R pathway functions, resulting in severe and overwhelming feelings of hunger (called polyphagia or hyperphagia). This is one of the primary mechanisms of hypothalamic obesity, a type of obesity that occurs as a result of damage to the hypothalamus. The MC4R pathway is also a therapeutic target for treatments for hypothalamic obesity.
A closer look at the MC4R pathway
Keep in mind that the below is a simplified explanation of a complex biological process. Also keep in mind that having a better understanding of this process can be helpful if you or a loved one is living with hypothalamic obesity—it can help you understand why the condition causes uncontrollable hunger, and why treatments for more common types of obesity have often been ineffective for treating hypothalamic obesity.
In neurology, a nucleus is a cluster of neurons (nerve cells) located within the brain or brainstem that share the same functions or connections. The plural is nuclei. The arcuate nucleus is one of the major nuclei in the hypothalamus.
A key function of the arcuate nucleus is monitoring how much fuel for energy the body has available. One way it does this is by monitoring leptin, a hormone that is released from fat cells (which store energy). When a person has enough energy, leptin levels are high.
The arcuate nucleus contains specialized neurons called POMC (pro-opiomelanocortin) neurons. When leptin levels are high, POMC neurons release a hormone called alpha-melanocyte stimulating hormone (alpha-MSH). This hormone attaches to MC4R receptors throughout the hypothalamus and other parts of the brainstem. This triggers the satiety signals that suppress appetite. It also tells the body it can burn more calories.
Again, keep in mind that this is a simplified explanation, and that other neurobiological processes in other organs (such as the gastrointestinal tract) are occurring alongside what is described here.
It's also helpful to mention ghrelin. This hormone has the opposite effect from leptin. It suppresses the activity of POMC neurons and the release of alpha-MSH, which increases hunger and tells a person to seek food.
MC4R pathway and hypothalamic obesity
When the hypothalamus is damaged—which can occur due to tumors, surgery, infections, or brain injuries—the MC4R pathway will no longer function normally. A person's appetite will be permanently switched on, leading to increased appetite and decreased satiety. Damage to the hypothalamus can also result in slower metabolism, hormone imbalances, fatigue, and multiple other factors that contribute to excess weight gain.
MC4R pathway as a target for hypothalamic obesity treatment
Hypothalamic obesity typically does not respond well to treatments for more common types of obesity, and there are currently no therapies indicated specifically for hypothalamic obesity.
However, research is ongoing, and new and emerging therapies are under development. One emerging therapy is a medication that acts on the melanocortin 4 receptor (MC4R) pathway. This medication activates MC4R receptors, which triggers the release of satiety signals.
Even with new therapies, treatment for hypothalamic obesity will remain a highly individualized process, a process that should be tailored to the specific needs of the person being treated, including coexisting health conditions, complications of obesity, and the underlying causes of the condition.
